CIA remains focused on driving growth through product development, expanding its distribution including international market penetration, and enhancing its agent/client service platforms. Elevated endowment maturities are near-term challenges. Our 2026 estimates reflect strong first-year sales growth translating into accelerating renewal-driven revenue. Our 2026 EPS estimate of $0.30 reflects a dip in benefit payments and 5% growth in premiums. We expect maturing endowment payments to peak in 2025 and that growth in renewal premiums will support margin expansion thereafter. Management highlighted CIA's domestic life insurance growth roadmap that includes expansion into an additional six states to reach 49 total, and continuing to capture share in the underserved final expense market. The balance sheet remains debt free and capital positioning is healthy, aided by CIA's reinsurance program. CIA recorded a record level of direct insurance in force of $5.38 billion at the end of 3Q:25 ($5.35 billion at 2Q:25), due to expanded distribution and sales of new products. In the investment portfolio, management is eyeing new allocations, including investment grade private placement fixed income securities; the company expects this will enhance yield going forward (average yield was 4.6% in 3Q:25). We increase our price target on CIA shares to $6 (from $5), based on applying a 16x multiple to our 2027 EPS estimate of $0.36. Previously, our $5 price target was based on a 0.80x multiple applied to our 2027 book value per share estimate of $7.12. Our updated valuation methodology better captures CIA's growth and fosters a closer comparison to peers, in our view. Our Moderate risk rating reflects CIA's rapid pace of growth and increasing capital requirements and liquidity needs.